STA®-Procoag-PPL

Midway between plasma haemostasis and cellular haemostasis are microparticles rich in procoagulant phospholipids. Increased procoagulant activity features in many diseases, including:

• cardiovascular diseases,
• certain types of cancer,
• inflammatory syndromes,
• infectious diseases,
• obstetric complications, etc.

STA®-Procoag-PPL, an easy to use standardised automated test, can be used to measure changes in procoagulant activity, facilitating study of this activity. phospholipids.

Procoagulant activity comes from phospholipids present at various sites:

• circulating microparticles
• activated platelets
• activated red and white cells.

This test has numerous benefits :

• Rapid: < 4 min
• Easy to use
• Excellent reproducibility
• Flexible: suitable for testing samples individually or in series
• Close to physiological characteristics: it may be used in PPP (platelet-poor plasma), PRP (platelet-rich plasma) or whole blood to investigate all sources of procoagulant phospholipids.

Results are expressed as coagulation times: the shorter the coagulation time the greater the procoagulant activity of the phospholipids being studied.

This new marker may be of value in:

• diagnostics, as a pre-thrombotic marker
• prognostics, as an early marker for certain diseases
• therapeutics, as an indicator for monitoring of anticoagulant therapy.

Thus, with STA®-Procoag-PPL, Stago adds to its range of flow cytometry and thrombin generation reagents for microparticle analysis.